Elicio Reports Three Complete Responses With ELI-002 7P in Metastatic Pancreatic Cancer
Elicio reports three complete responses with ELI-002 7P in metastatic pancreatic cancer patients receiving subsequent checkpoint inhibitor therapy.
uniQure Plans BLA Submission for AMT-130 Gene Therapy in Huntington’s Disease
uniQure plans BLA submission for AMT-130 gene therapy in Huntington's disease, targeting Q3 2026 based on 36-month efficacy data.
Olorofim Meets Non-Inferiority Goal in Phase 3 Invasive Aspergillosis Trial
Olorofim meets non-inferiority goal in Phase 3 invasive aspergillosis trial, showing 23.8% mortality versus 24.3% for AmBisome with significantly...
FDA Approves Utebzi, First Oral Carbapenem for Complicated UTIs
FDA approves oral carbapenem Utebzi for complicated UTIs, offering an IV-to-oral step-down option for hospitalized patients with resistant infections.
FDA Accepts Lunsumio and Polivy Combo for Relapsed Refractory B-Cell Lymphoma
FDA accepts Lunsumio and Polivy combo for relapsed refractory B-cell lymphoma, with phase III data showing 11.5-month median PFS...
Ligufalimab Plus Azacitidine and Venetoclax Shows OS Benefit in AML Phase II
Ligufalimab plus azacitidine and venetoclax achieved 78.7% nine-month OS rate in AML, nearly doubling response duration versus standard care...
Selinexor-Ruxolitinib Combination Meets Primary Endpoint in Myelofibrosis Trial
Selinexor-Ruxolitinib combination achieves 49.8% spleen volume reduction at week 24 in phase 3 myelofibrosis trial, significantly outperforming ruxolitinib mono
TransCon PTH Maintains Response in 86% of Hypoparathyroidism Patients at 3.5 Years
TransCon PTH maintains response in 86% of hypoparathyroidism patients at 3.5 years, with improved kidney function and sustained biochemical...
Selinexor Plus Ruxolitinib Meets Primary Endpoint in Myelofibrosis Trial
Selinexor plus ruxolitinib met its primary spleen response endpoint in myelofibrosis, with 49.8% achieving SVR35 versus 28% on ruxolitinib...
Atumelnant cuts androgen levels 67% while reducing glucocorticoid doses in CAH trial
Atumelnant cuts androgen levels 67% while reducing glucocorticoid doses to physiologic levels in CAH trial, advancing toward Phase 3.